Media stories about Eleven Biotherapeutics (NASDAQ:EBIO) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.7340537614336 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Eleven Biotherapeutics (NASDAQ:EBIO) opened at $0.85 on Friday. The firm has a market cap of $27.19, a P/E ratio of -0.81 and a beta of 3.04. Eleven Biotherapeutics has a 52-week low of $0.62 and a 52-week high of $2.54.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Eleven Biotherapeutics (EBIO) Share Price” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/eleven-biotherapeutics-ebio-receives-daily-media-impact-score-of-0-24.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.